Researchers from the University of Geneva (UNIGE) and the Ludwig Maximilians Universität München (LMU) say they have succeeded in using an in vitro screening technique to develop a fully biodegradable nanoparticle capable of delivering a new anti-inflammatory drug directly into macrophages, where uncontrolled inflammatory reactions are triggered.
The study “Inhibition of IL-1beta release from macrophages targeted with necrosulfonamide-loaded porous nanoparticles,” which appears in the Journal of Controlled Release, opens the door to a powerful and targeted anti-inflammatory treatment, according to the scientists.
